Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
In previously treated nAMD eyes, intravitreal faricimab was associated with increased mean treatment interval and decreased CST but no improvement in mean BCVA. The benefit of faricimab on CST reduction may be diminished in eyes previously treated with multiple different types of anti-VEGF therapy.
Authors
- Abraham Hang (ORCID: https://orcid.org/0000-0001-7282-1834)
- Kareem Moussa (ORCID: https://orcid.org/0000-0001-9110-9594)
- Taylor Ngo
- Susanna S. Park (ORCID: https://orcid.org/0000-0001-5911-6671)
- Parisa Emami-Naeini (ORCID: https://orcid.org/0000-0002-4494-7517)
- Ala Moshiri (ORCID: https://orcid.org/0000-0002-4277-8094)
- Jaipreet Singh Virk
Institutions
- University of California, Davis (US)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/opth.s494605
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.15